The cancer diagnostics company is hours away from losing funding for its tests through the US Medicare system.
A possible sell-down of Fletcher Building’s $1b land assets, subject of speculation in Australian media, is seen as a way to boost its balance sheet.
Problems with alternative jet fuel availability and the inability to upgrade its fleet effectively have hindered the airline’s science-based carbon reduction goals.
NZX-listed recruitment firm’s stock up 51% in 14 days, but says it has complied with continuous disclosure rules.
Unaudited figures for the NZX-listed honey company have come in below expectations.
Distribution vessel Aotearoa Chief in dock at Northport for repairs.
Brent King asked whether it was worth listing on the NZX, a 'government-sanctioned monopoly’.
Long-time Mainfreight director receives thumbs down from some shareholders over $120,000 payment.
Lines company announces conditional sale of LPG business for $150m.
Novitas, the US Medicare Administrative Contractor, delays making final decision on removing Cxbladder from its approved test list.